Regulatory
Sep 22, 2026 · 1 min read · 77,597 views
Roivant's road to a potential blockbuster begins with FDA approval for Lisraya
D
Daniel Park
Editorial · Sep 22, 2026
Reports indicate that the FDA approved Roivant's dermatomyositis drug brepocitinib on Thursday, the first major regulatory nod that could usher in a multibillion-dollar revenue stream for the
← Previous
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
Next →
Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms
